- BioFIT 2010
- Coopération Européenne
- BioFIT 2010
- NutrEvent 2011
- The Nutrition, Healthcare, Longevity Cluster
Genfit: milestone achieved as a coumpound developed in partnership enters the clinic
Lille (France), Cambridge (Massachusetts, United States), May 6th, 2010 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the achievement of a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners. Thanks to the joint efforts of the research teams of the two companies, a ‘first-in-class’ compound with an original mechanism of action for the treatment of cardiometabolic disorders is today entering clinical trials.
Jean-François Mouney, Chairman of GENFIT’s Management Board, declared: “We are very pleased to see a molecule originating from one of our research partnerships successfully achieve an important phase in its development. This provides strong recognition by the pharmaceutical industry of our scientific expertise and of the relevance of our research targets. This is the second program to enter clinical trials from this strategic collaboration initiated 8 years ago. This new achievement underlines the talent of our research teams, as well as those of our partner. We are confident that our innovative and collaborative approach will provide an efficient therapeutic strategy for cardiometabolic diseases and associated causes of mortality and morbidity.”
In addition to this initial milestone, GENFIT will potentially receive further clinical development-based milestone payments, as well as royalties on future sales.
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neurodegenerative disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, Alzheimer’s…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health concerns and their unmet medical needs. GENFIT’s proprietary research programs and its partnerships with leading pharmaceutical companies, including SANOFI-AVENTIS, SOLVAY GROUP, and SERVIER, have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and two other compounds, in partnership with SANOFI-AVENTIS and SOLVAY, are in the advanced stages of Phase I.
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 120 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Jean-François Mouney – Chairman of the Management Board
+33 (0)3 2016 4000
MILESTONES – Press Relations
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – email@example.com